Name: La Roche-Posay Effaclar Duo+ M
Brand: La Roche-Posay (L'Oréal)

Alina · AI avatar

Episode 02 · “Is it worth the hype?” · 2 min 42 s · Every claim spoken on screen maps to an approved claim below. Featuring the gentleman in pink (silent).

Snapshot

Good product. Inflated story.

A light, fast-absorbing, matte gel-cream with a genuinely gentle acid load — the identical formula is US-registered at salicylic acid 0.5 %, well below the EU leave-on limit of 2 %. The actives are the standard, plausible toolkit for mild-to-moderate blemish-prone skin. So why Caution, not Recommended? Because every headline number the brand advertises traces only to its own unpublished studies — with sample sizes that contradict each other across La Roche-Posay’s own country websites — and because “hypoallergenic, ideal for sensitive skin” is claimed on a fragranced salicylic-acid leave-on. We publish it with a narrowed claim set and mandatory warnings.

Five dimensions · never averaged into one number

Evidence quality Headline figures are manufacturer-funded and unpublished; sample sizes contradict each other across the brand’s own sites. Cochrane grades independent evidence for this ingredient class low to very low.

Product performance A randomised clinician-blind hospital trial (n=64) found better comedone clearance than 5 % BPO from day 28; texture benefits replicate across three independent review bases. But responses are strongly bimodal.

User fit Unusually well defined: oily to combination, blemish-prone, mild-to-moderate acne, teens to ~35 — as the moisturiser step. One point off: the brand over-extends to “sensitive skin” and “from age 10”.

Value 42.13 €/100 ml at the best DE price. Undercuts Paula’s Choice by a third — but costs 21 % more than L’Oréal’s own fragrance-free CeraVe gel, and its own users rate value 2.0/5.

Trust Ingredient disclosure is exemplary — full INCI, EAN, PZN, legal entity, even an exact active concentration in the US registration. The marketing around it is what costs points.

The Trust Standard treats a low Evidence score next to a high User-Fit score as the informative result: a product that plausibly suits a well-defined user, sold with claims its evidence can’t carry.

The claim audit

What the brand says vs. what survives

Removed — we don’t repeat these

Struck from every script, card, caption and thumbnail.

“−44 % blemishes · −45 % marks · −66 % blackheads”Unpublished internal studies · sample sizes contradict across brand sites

“First visible results in just 8 hours”54 vs. 45 vs. 100 subjects for the same claim

“Clinically proven · tested on 17,000+ subjects”Brand’s own pages state 17,000 and 11,014 — both can’t be true

“Hypoallergenic · non-comedogenic”Unverifiable · formula contains fragrance; one ingredient rated comedogenic 5/5

“Ideal for sensitive skin”Fragranced salicylic-acid leave-on · burning reports cluster in this group

“UK’s #1 · 9/10 dermatologists recommend”Survey of attendees at a brand-sponsored symposium

“Suitable from 10 years old”EU advisers flag open safety questions for ages 3–10

Approved — cleared for ALINA

Publish-ready wording, each bound to sources.

“The exfoliating strength is low: the identical formula is US-registered with salicylic acid 0.5 % — well below the EU leave-on limit of 2 %. Expect gentle, not aggressive.” DailyMed · FDA labelEU Reg. 1223/2009

“LHA penetrates less than salicylic acid (6 % vs. 58 %) while forming a larger surface reservoir — and reduced follicular casts by 47 % in number in a split-face study.” PMC5300717 · peer-reviewed

“In a randomised clinician-blind trial (Shanghai, n=64), this formula family combined with 5 % BPO cleared lesions fastest; alone, it beat BPO on comedone clearance from day 28.” PMC9433072 · independent site

“Unlike retinoic acid or benzoyl peroxide, this formula family did not significantly reduce skin bacterial diversity — the gentler option on the microbiome.” PubMed 36841971

“The most consistently confirmed benefit is texture: light gel-cream, absorbs fast, non-greasy, matte finish, works under make-up.” 3 independent review bases

“Contains niacinamide — trial evidence for fading pigment exists at 4 % — but La Roche-Posay does not disclose the concentration used here.” PMC3142702SkinCarisma

“Manage expectations: independent evidence for this class of ingredients is graded low to very low by Cochrane. Effect, yes; miracle, no.” Cochrane CD011368Stiftung Warentest

The reformulation — do not smooth this over

Two ratings. Both real.

Duo+ M is a reformulation and renaming of the long-running Effaclar Duo(+): linoleic acid out; Vitreoscilla ferment, mannose and pomegranate pericarp in. A large group of long-term users report the new version made things worse for them — while new users at pharmacies rate it highly. We show both numbers.

1.8/5

Efficacy on La Roche-Posay’s own German site
2,048 reviews · value rated 2.0/5 · top critical review: a reformulation complaint with 144 helpful votes

4.6/5

Average at German pharmacy retailers
596 reviews at Shop-Apotheke · 4.9/5 at Notino (45) · texture praise dominates

Also not the same product as the recall: the FDA’s March 2025 benzene recall named “Effaclar Duo Dual Action” — a US benzoyl-peroxide product, one lot. Effaclar Duo+ M contains no benzoyl peroxide and was not recalled. We state this proactively because search traffic conflates the two names.

Audience fit · mandatory language

Who it’s for. Who should skip it.

Evidence-backed fit

Oily to combination, blemish-prone skin — positioned as a moisturiser, not a spot treatment
Mild to moderate acne (GEA grade 1–2) — the only severity range with any evidence
Congested pores, blackheads, post-acne marks, shine
As the moisturiser layer alongside prescribed BPO, adapalene or azelaic acid — applied 30 min apart
From about age 12, with adult supervision — we don’t repeat the brand’s “from 10”

Caution or poor fit

Pregnancy / breastfeeding: ask a doctor or pharmacist — regulators and dermatology reviews disagree, and we show that instead of resolving it
Fragrance allergy or reactive, sensitised skin: contains Parfum — patch-test first; burning/redness is the top complaint pattern
Rosacea, damaged barrier, active dermatitis: avoid or introduce very gradually
Severe or cystic acne: not an appropriate primary treatment — see a dermatologist
Dry skin as primary type: dryness complaints cluster here — choose a richer, acid-free moisturiser
Eye area: keep away — salicylic acid is classified as causing serious eye damage (H318)
Sun: apply sunscreen when going outside — per the US drug label of this formula

Transparency check

Marketing names, decoded

The single most useful number in this dossier: the US registration of the identical ingredient list declares salicylic acid 0.5 % as the active. No other concentration is disclosed in any market.

Brand says	INCI reality	Independent evidence
“Phylobioma Active”	Vitreoscilla Ferment — a rebranded, previously marketed ingredient (Aqua Posae Filiformis)	No independent acne trial found; one human trial in seborrhoeic dermatitis, details unreported
“Procerad”	2-Oleamido-1,3-Octadecanediol, a ceramide-type molecule	No independent published trial found — trademark-level claim
“LHA”	Capryloyl Salicylic Acid (lipohydroxy acid)	The most interesting active: specific comedolytic data in peer-reviewed work (−47 % follicular casts)
“Niacinamide”	Position 5 in the INCI — concentration undisclosed	Pigment evidence exists at 4 %; we can’t confirm this product delivers a studied dose
“Thermal spring water”	Not separately declared in the German INCI — only Aqua/Water	Flagged divergence between brand story and pack

Price-performance · verified 20 Aug 2026 · German market

Where to buy, disclosed

Merchant	Price · 40 ml	€ / 100 ml	Note
dm.de	16.85 €	42.13 €	Reference low
Rossmann	17.99 €	44.98 €
Aliva	17.99 €	44.98 €	−18 % vs. RRP
DocMorris	19.29 €	48.23 €
Shop-Apotheke	19.49 €	48.73 €	2×40 ml bundle: 45.99 €/100 ml
RRP	21.90 €	54.75 €	Spread: 16.85–24.45 € for the same tube

dm.de16.85 €Affiliate link · disclosed Shop-Apotheke19.49 €Affiliate link · disclosed DocMorris19.29 €Affiliate link · disclosed

Demo prototype: redirects disabled. In production every click stores network, merchant, disclosure version and a non-personal reference — and no affiliate status can override claim status, ranking or chat answers.

Honest alternatives

Product	€ / 100 ml	Trade-off
CeraVe Anti-Blemish Gel · 40 ml · 13.85 €	34.63 €	21 % cheaper, fragrance-free, three ceramides — but also a L’Oréal brand, which we disclose
Paula’s Choice CLEAR Moisturizer · 60 ml · 38.00 €	63.33 €	Effaclar is a third cheaper and adds two exfoliating acids — Effaclar wins on value here
The Ordinary Niacinamide 10 % + Zinc · from 5.20 €	17.33 €	Disclosed high niacinamide dose — but a serum, no acids, and its maker states it’s not an acne treatment

Conflict of interest · standing rule

Independence, on the record

§1

No relationship

No affiliate, sponsorship or commercial agreement with La Roche-Posay or L’Oréal informed this dossier. No samples received, no brand contact made — as of 20 August 2026.

§2

Disclosed overlaps

The “cheaper alternative” CeraVe routes revenue to the same L’Oréal group — we say so. The strongest supporting trial was authored by La Roche-Posay’s own researchers — we flag it wherever cited.

§3

The standing rule

Sponsoring pays for reach, never for the evaluation result. Any future commercial relationship triggers re-verification by an uninvolved reviewer — and on-page disclosure.

Key sources · every value URL-bound at verification

DailyMed · US OTC label (SA 0.5 %) SCCS Opinion 2023 · salicylic acid Cochrane CD011368 Shanghai RCT · PMC9433072 LHA review · PMC5300717 Microbiome RCT · PubMed 36841971 150-subject RCT · jocd.16052 (L’Oréal-authored) dm.de · INCI & price larocheposay.de · claims & reviews FDA · 2025 recall (different SKU) AAD 2024 guideline INCIDecoder

Revalidation triggers: any INCI change, any change to the declared 0.5 % level, new EU action on salicylic acid, any recall naming an Effaclar SKU, publication of an independent trial (the one change that could move this verdict to Recommended), or a DE price move beyond ±15 %. Expiry: 20 August 2027.

How we verify — the Trust Standard